These innovative medications , Semaglutide , represent a significant advancement in managing metabolic dysfunction and possibly associated disorders. They all are classified as GLP-1 pathway agonists , signifying they to replicate the endogenous GLP-1 hormone , stimulating glucose production and reducing appetite . Despite Semaglutide each works re